In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Globus Prepared for Trek with $110m from Clarus-led Group

Executive Summary

Clarus Ventures placed an unusually big bet for the orthopedics industry by leading a syndicate of private equity investors in a $110 million Series E round in Globus Medical Inc. But the four-year-old company is well ahead of its peers with more than $100 million in sales and a line of fusion products on the market. The company faces the challenge of introducing a new line of non-fusion and biomaterial products if it hopes to grow into the industry leader its investors expects it to be.

You may also be interested in...



Globus IPO Bid Is Good News For Spine Industry

Globus Medical filed for an initial public offering of stock in March, making it the first spine company to test the public markets since TranS1 raised $86 million in its own IPO at the tail end of 2007.

Welsh Carson Sits in K2M Driver's Seat

With the backing of the private equity powerhouse Welsh Carson, K2M will look to grow beyond its historical niche in complex spinal cases, though it will have to do so without any financial ties to the surgeons who once owned part of the company.

Welsh Carson Sits in K2M Driver's Seat

With the backing of the private equity powerhouse Welsh Carson, K2M will look to grow beyond its historical niche in complex spinal cases, though it will have to do so without any financial ties to the surgeons who once owned part of the company.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV002992

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel